Guilin Sanjin(002275)2025-05-10 03:06Financial Performance - In 2024, the company achieved total revenue of 2,193.99 million CNY, a growth of 1.03% compared to 2023's 2,171.60 million CNY [1] - The total profit reached 643.94 million CNY, an increase of 24.24% from 518.28 million CNY in the previous year [1] - Net profit attributable to shareholders was 521.53 million CNY, up 23.79% from 421.30 million CNY year-on-year [1] - In Q1 2025, the net profit after deducting non-recurring gains and losses was 97.67 million CNY, reflecting an 11.61% increase from 87.52 million CNY in Q1 2024 [1] Business Development - The biopharmaceutical sector is a key part of the company's dual-wing strategy, facing high investment and long R&D cycles, with current market conditions being challenging [1] - The company is experiencing increased competition and a diverse customer base, leading to some idle capacity in the CDMO supply chain [1] - Ongoing projects in the biopharmaceutical pipeline are still in the R&D phase, with limited revenue from technical services [1] - The company is optimizing costs and personnel structure while focusing on promising projects, such as the BC006 monoclonal antibody injection, which is nearing completion of Phase I clinical trials [1] Inventory and Sales Management - The company has upgraded its inventory management system, utilizing BI analytics to enhance market demand alignment and cost control [2] - The overall inventory level has improved significantly, maintaining a healthy cycle of 1.5 to 2 months, which supports operational quality and cost optimization [2] - The company has implemented diverse promotional activities to stimulate market demand and optimize inventory across channels [2] Product Growth and Dividends - The growth trend for second and third-tier products remains positive, with specific products like the Guaifenesin capsule expected to continue strong growth [2] - The company plans to maintain its cash dividend policy, proposing a distribution of 3.5 CNY per 10 shares, totaling 206 million CNY for 2024 [2] Sales Expense Management - The company has adopted a more precise approach to sales expense allocation, focusing on second and third-tier products while maintaining a low expense ratio for first-tier products [3] - Overall sales expenses are aligned with sales revenue, indicating no significant changes in the sales expense ratio for the year [3]